Cargando…
Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?
INTRODUCTION: The retina is a potential source of noninvasive vascular biomarkers for Alzheimer's disease (AD). We assessed retinal microvasculature in well-characterized AD cases, taking ophthalmological confounders into account. METHODS: We included 48 amyloid-positive AD patients and 38 amyl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517376/ https://www.ncbi.nlm.nih.gov/pubmed/31193094 http://dx.doi.org/10.1016/j.dadm.2019.03.006 |
_version_ | 1783418263050387456 |
---|---|
author | den Haan, Jurre van de Kreeke, Jacoba A. van Berckel, Bart N. Barkhof, Frederik Teunissen, Charlotte E. Scheltens, Philip Verbraak, Frank D. Bouwman, Femke H. |
author_facet | den Haan, Jurre van de Kreeke, Jacoba A. van Berckel, Bart N. Barkhof, Frederik Teunissen, Charlotte E. Scheltens, Philip Verbraak, Frank D. Bouwman, Femke H. |
author_sort | den Haan, Jurre |
collection | PubMed |
description | INTRODUCTION: The retina is a potential source of noninvasive vascular biomarkers for Alzheimer's disease (AD). We assessed retinal microvasculature in well-characterized AD cases, taking ophthalmological confounders into account. METHODS: We included 48 amyloid-positive AD patients and 38 amyloid-negative cognitively normal control subjects. All participants underwent ophthalmological screening to exclude interfering ocular disease. Using a multimodal approach, we measured retinal vascular parameters, choroidal thickness, macular vascular density, and foveal avascular zone size. RESULTS: We found no disease effects on retinal vascular measures (all β′s < |0.15|, all P > .2), adjusted for confounders. Venular tortuosity was inversely associated with Fazekas score in control subjects (β −0.56, P < .01), while vessel density in the outer ring of the macula was inversely associated with Fazekas score in AD cases (β −0.64, P < .01). DISCUSSION: In conclusion, retinal vasculature did not discriminate patients with AD from control subjects, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid biomarkers, challenging the use of retinal vasculature measurements as AD biomarker. |
format | Online Article Text |
id | pubmed-6517376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-65173762019-05-21 Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? den Haan, Jurre van de Kreeke, Jacoba A. van Berckel, Bart N. Barkhof, Frederik Teunissen, Charlotte E. Scheltens, Philip Verbraak, Frank D. Bouwman, Femke H. Alzheimers Dement (Amst) Retinal Imaging INTRODUCTION: The retina is a potential source of noninvasive vascular biomarkers for Alzheimer's disease (AD). We assessed retinal microvasculature in well-characterized AD cases, taking ophthalmological confounders into account. METHODS: We included 48 amyloid-positive AD patients and 38 amyloid-negative cognitively normal control subjects. All participants underwent ophthalmological screening to exclude interfering ocular disease. Using a multimodal approach, we measured retinal vascular parameters, choroidal thickness, macular vascular density, and foveal avascular zone size. RESULTS: We found no disease effects on retinal vascular measures (all β′s < |0.15|, all P > .2), adjusted for confounders. Venular tortuosity was inversely associated with Fazekas score in control subjects (β −0.56, P < .01), while vessel density in the outer ring of the macula was inversely associated with Fazekas score in AD cases (β −0.64, P < .01). DISCUSSION: In conclusion, retinal vasculature did not discriminate patients with AD from control subjects, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid biomarkers, challenging the use of retinal vasculature measurements as AD biomarker. Elsevier 2019-05-10 /pmc/articles/PMC6517376/ /pubmed/31193094 http://dx.doi.org/10.1016/j.dadm.2019.03.006 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Retinal Imaging den Haan, Jurre van de Kreeke, Jacoba A. van Berckel, Bart N. Barkhof, Frederik Teunissen, Charlotte E. Scheltens, Philip Verbraak, Frank D. Bouwman, Femke H. Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? |
title | Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? |
title_full | Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? |
title_fullStr | Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? |
title_full_unstemmed | Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? |
title_short | Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? |
title_sort | is retinal vasculature a biomarker in amyloid proven alzheimer's disease? |
topic | Retinal Imaging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517376/ https://www.ncbi.nlm.nih.gov/pubmed/31193094 http://dx.doi.org/10.1016/j.dadm.2019.03.006 |
work_keys_str_mv | AT denhaanjurre isretinalvasculatureabiomarkerinamyloidprovenalzheimersdisease AT vandekreekejacobaa isretinalvasculatureabiomarkerinamyloidprovenalzheimersdisease AT vanberckelbartn isretinalvasculatureabiomarkerinamyloidprovenalzheimersdisease AT barkhoffrederik isretinalvasculatureabiomarkerinamyloidprovenalzheimersdisease AT teunissencharlottee isretinalvasculatureabiomarkerinamyloidprovenalzheimersdisease AT scheltensphilip isretinalvasculatureabiomarkerinamyloidprovenalzheimersdisease AT verbraakfrankd isretinalvasculatureabiomarkerinamyloidprovenalzheimersdisease AT bouwmanfemkeh isretinalvasculatureabiomarkerinamyloidprovenalzheimersdisease |